نتایج جستجو برای: ژن kras

تعداد نتایج: 23037  

Journal: :Frontiers in Immunology 2023

Three rat sarcoma (RAS) gene isoforms, KRAS, NRAS, and HRAS, constitute the most mutated family of small GTPases in cancer. While development targeted immunotherapies has led to a substantial improvement overall survival patients with non-KRAS-mutant cancer, RAS-mutant cancers have an poorer prognosis owing high aggressiveness tumors. KRAS mutations are strongly implicated lung, pancreatic, col...

Journal: :Cancer research 2014
Carles Barceló Noelia Paco Mireia Morell Blanca Alvarez-Moya Neus Bota-Rabassedas Montserrat Jaumot Felip Vilardell Gabriel Capella Neus Agell

KRAS phosphorylation has been reported recently to modulate the activity of mutant KRAS protein in vitro. In this study, we defined S181 as a specific phosphorylation site required to license the oncogenic function of mutant KRAS in vivo. The phosphomutant S181A failed to induce tumors in mice, whereas the phosphomimetic mutant S181D exhibited an enhanced tumor formation capacity, compared with...

Journal: :Journal of clinical pathology 2015
Umberto Malapelle Roberta Sgariglia Alfonso De Stefano Claudio Bellevicine Elena Vigliar Dario de Biase Romina Sepe Pierlorenzo Pallante Chiara Carlomagno Giovanni Tallini Giancarlo Troncone

AIMS Patients with colorectal cancer harbouring KRAS mutations do not respond to antiepidermal growth factor receptor (anti-EGFR) therapy. Community screening for KRAS mutation selects patients for treatment. When a KRAS mutation is identified by direct sequencing, mutant and wild type alleles are seen on the sequencing electropherograms. KRAS mutant allele-specific imbalance (MASI) occurs when...

2011
Wanglong Qiu Fikret Sahin Christine A. Iacobuzio-Donahue Dario Garcia-Carracedo Wendy M. Wang Chia-Yu Kuo Doris Chen Dan E. Arking Andrew M. Lowy Ralph H. Hruban Helen E. Remotti Gloria H. Su

Inactivation of tumor suppressor gene p16/INK4A and oncogenic activation of KRAS occur in almost all pancreatic cancers. To better understand the roles of p16 in pancreatic tumorigenesis, we created a conditional p16 knockout mouse line (p16flox/flox), in which p16 is specifically disrupted in a tissue-specific manner without affecting p19/ARF expression. p16flox/flox; LSL-KrasG12D; Pdx1-Cre mi...

2010
Sylwia Jančík Jiří Drábek Danuta Radzioch Marián Hajdúch

The KRAS gene (Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) is an oncogene that encodes a small GTPase transductor protein called KRAS. KRAS is involved in the regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Activating mutations in the KRAS gene impair the ability of the KRAS protein to switch between active and inactive states, leadi...

Journal: :Journal of the National Cancer Institute 2012
Nathan T Ihle Lauren A Byers Edward S Kim Pierre Saintigny J Jack Lee George R Blumenschein Anne Tsao Suyu Liu Jill E Larsen Jing Wang Lixia Diao Kevin R Coombes Lu Chen Shuxing Zhang Mena F Abdelmelek Ximing Tang Vassiliki Papadimitrakopoulou John D Minna Scott M Lippman Waun K Hong Roy S Herbst Ignacio I Wistuba John V Heymach Garth Powis

BACKGROUND Mutations in the v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) play a critical role in cancer cell growth and resistance to therapy. Most mutations occur at codons 12 and 13. In colorectal cancer, the presence of any mutant KRas amino acid substitution is a negative predictor of patient response to targeted therapy. However, in non-small cell lung cancer (NSCLC), the ev...

Journal: :Cell 2014
Diane D. Shao Wen Xue Elsa B. Krall Arjun Bhutkar Federica Piccioni Xiaoxing Wang Anna C. Schinzel Sabina Sood Joseph Rosenbluh Jong W. Kim Yaara Zwang Thomas M. Roberts David E. Root Tyler Jacks William C. Hahn

Cancer cells that express oncogenic alleles of RAS typically require sustained expression of the mutant allele for survival, but the molecular basis of this oncogene dependency remains incompletely understood. To identify genes that can functionally substitute for oncogenic RAS, we systematically expressed 15,294 open reading frames in a human KRAS-dependent colon cancer cell line engineered to...

2013
Jong-Mu Sun Deok Won Hwang Jin Seok Ahn Myung-Ju Ahn Keunchil Park

Clinical implications of KRAS mutations in advanced non-small cell lung cancer remain unclear. We retrospectively evaluated the prognostic and predictive value of KRAS mutations in patients with advanced NSCLC. Among 484 patients with available results for both KRAS and EGFR mutations, 39 (8%) had KRAS and 182 (38%) EGFR mutations, with two cases having both mutations. The median overall surviv...

2013
Carles Barceló Noelia Paco Mireia Morell Blanca Alvarez-Moya Neus Bota Montserrat Jaumot Felip Vilardell Gabriel Capella Neus Agell

26 KRAS phosphorylation has been reported recently to modulate the activity of mutant 27 KRAS protein in vitro. In this study, we defined S181 as a specific phosphorylation site 28 required to license the oncogenic function of mutant KRAS in vivo. The phosphomutant 29 S181A failed to induce tumors in mice, whereas the phosphomimetic mutant S181D 30 exhibited an enhanced tumor formation capacity...

2014
Yu-Lin Lin Yi-Hsin Liang Jia-Huei Tsai Jau-Yu Liau Jin-Tung Liang Been-Ren Lin Ji-Shiang Hung Liang-In Lin Li-Hui Tseng Yih-Leong Chang Kun-Huei Yeh Ann-Lii Cheng

To identify better regimens in currently available chemotherapy would be beneficial to KRAS mutant metastatic colorectal cancer (mCRC) patients because they have fewer treatment options than KRAS wild-type mCRC patients. Clinicopathologic features and overall survival (OS) of KRAS mutant and wild-type mCRC patients who had used oxaliplatin-based, irinotecan-based, bevacizumab-based, as well as ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید